Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Enzolinion Jan 29, 2020 9:54am

120 Views

Post# 30613611

RE:Really?

So enough is enough!!! I had a few conversations with a loser on the this board who lives in toronto area and works at a big bank, who had asked me if I wanted to start shorting Kaly and bash them on stockhouse. This was about a 8 months ago when he asked at the time he was a big believer in kaly but I found it odd that he asked me to do that anyways he was and is a loser that invested his moms life savings in kaly!!! Again I have passed his name on to some people and hopefully they will find him. I think his name started with a G?????

Bullboard Posts

Gold Flora's Gramlin holds court in California cannabis market